Accretion Pha.

Why is Accretion Pharmaceuticals Ltd falling/rising?

As of 23-Jun, Accretion Pharmaceuticals Ltd's stock price is rising to 145.50, up 2.72%, driven by strong recent performance compared to the Sensex and positive moving averages, despite a decline in investor participation.

As of 23-Jun, Accretion Pharmaceuticals Ltd's stock price is rising, currently at 145.50, reflecting an increase of 3.85 or 2.72%. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 1.75% while the Sensex declined by 0.69%. Additionally, the stock has shown impressive performance over the last month, with a significant increase of 30.43% compared to a modest 0.44% rise in the Sensex. Year-to-date, the stock has surged by 65.62%, while the Sensex has fallen by 8.82%, indicating strong relative strength.<BR><BR>Moreover, the stock's performance today has outpaced its sector by 1.97%. It is also trading above its 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a positive trend. However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping by 47.67% against the 5-day average. Despite this, the stock remains liquid enough for trading, which supports its price stability.<BR><BR>Overall, the combination of strong recent performance relative to the market and sector, along with favorable moving averages, contributes to the rising stock price of Accretion Pharmaceuticals Ltd.

Which are the latest news on Accretion Pha.?

What does Accretion Pha. do?

Accretion Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 148 Cr. It currently has no reported sales or profits, a P/E ratio of 16.00, and a debt-equity ratio of 0.15.

Overview: Accretion Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: The incorporation year and any status changes are not provided, and there are no sales or profit reports available for the latest quarter.<BR><BR>Financial Snapshot: Most recent Net Sales: N/A; Most recent Net Profit: N/A; Market-cap value: INR 148 Cr (Micro Cap).<BR><BR>Key Metrics: P/E: 16.00; Industry P/E: 34; Dividend Yield: 0.00%; Debt-Equity: 0.15; Return on Equity: 17.68%; Price-to-Book: 2.71.<BR><BR>Contact Details: Registrar Address: Not available; Phone: N/A; Email: N/A; Website: N/A.

How big is Accretion Pha.?

As of 10th June, Accretion Pharmaceuticals Ltd has a market capitalization of 148.00 Cr, classifying it as a Micro Cap. There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Accretion Pharmaceuticals Ltd has a market capitalization of 148.00 Cr, classifying it as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 15.29 Cr and Total Assets totaling 39.87 Cr.

Who are the peers of the Accretion Pha.?

Accretion Pha.'s peers include Quest Laboratories, Alpa Laboratorie, Krebs Biochem, Bal Pharma, Parnax Lab, Kimia Bioscien., Achyut Healthcare, Auro Labs, and Smruthi Organic. Accretion Pha. shows excellent management and growth, with a 1-year return of 76.99%, significantly outperforming its peers.

Peers: The peers of Accretion Pha. are Quest Laborato., Alpa Laboratorie, Krebs Biochem, Bal Pharma, Parnax Lab, Kimia Bioscien., Achyut Healthcar, Auro Labs., and Smruthi Organic.<BR><BR>Quality Snapshot: Excellent management risk is observed at Accretion Pha., while Good management risk is found at Quest Laborato. Average management risk is noted at Alpa Laboratorie, Bal Pharma, and Auro Labs., and the rest have Below Average management risk. Excellent growth is seen at Accretion Pha. and Parnax Lab, while Good growth is observed at Quest Laborato. Average growth is noted at Achyut Healthcar, and the rest have Below Average growth. Excellent capital structure is found at Alpa Laboratorie and Parnax Lab, while Good capital structure is observed at Accretion Pha. and Smruthi Organic, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: Accretion Pha. has a 1-year return of 76.99%, which is higher than Quest Laborato.'s 1-year return of 7.07% and Alpa Laboratorie's -31.97%. The peer with the lowest 1-year return is Alpa Laboratorie at -31.97%. Additionally, peers with a negative six-month return include Alpa Laboratorie and Krebs Biochem.

Is Accretion Pha. overvalued or undervalued?

As of November 27, 2025, Accretion Pharmaceuticals is considered overvalued with a PE ratio of 15.23 and an EV to EBITDA of 9.35, despite a recent 63.82% stock return, as it is still more attractively priced than peers like Sun Pharma and Divi's Lab, which have much higher PE ratios.

As of 27 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently assessed as overvalued. Key ratios include a PE ratio of 15.23, an EV to EBITDA of 9.35, and a ROCE of 20.47%. <BR><BR>In comparison to its peers, Accretion's PE ratio is significantly lower than Sun Pharma's 37.62 and Divi's Lab's 69.34, both categorized as very expensive. This suggests that while Accretion may appear expensive relative to its own historical valuation, it is still more attractively priced compared to some of its higher-valued competitors. Despite recent stock performance showing a 63.82% return over the past month compared to a mere 0.96% for the Sensex, the overall valuation metrics indicate that Accretion Pharmaceuticals is not justified at its current price level.

How has been the historical performance of Accretion Pha.?

Accretion Pha. has shown significant growth from March 2024 to March 2025, with net sales increasing from 13.35 Cr to 57.38 Cr, and profit after tax rising from 1.49 Cr to 6.79 Cr. Key metrics such as operating profit and earnings per share also improved markedly, indicating strong overall financial performance.

Answer:<BR>The historical performance of Accretion Pha. shows significant growth over the past three years, particularly from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Accretion Pha. experienced a substantial increase in net sales, rising from 13.35 Cr in March 2024 to 57.38 Cr in March 2025. This growth in total operating income was accompanied by a rise in raw material costs, which increased from 15.17 Cr to 43.71 Cr during the same period. The total expenditure also rose significantly, from 10.79 Cr to 45.50 Cr. However, the operating profit (PBDIT) improved markedly, reaching 11.97 Cr in March 2025, up from 2.61 Cr in March 2024. Profit before tax also saw a notable increase, climbing to 9.76 Cr from 2.00 Cr. Consequently, profit after tax surged to 6.79 Cr in March 2025, compared to 1.49 Cr in March 2024. The earnings per share (EPS) reflected this growth, increasing from 3.73 to 8.31. On the balance sheet, total assets grew from 27.44 Cr to 39.87 Cr, while total liabilities increased from 27.44 Cr to 39.87 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities improved from -11.00 Cr to 5.00 Cr, showcasing a positive shift in cash generation. Overall, Accretion Pha. demonstrated a strong upward trend in financial performance across key metrics.

When is the next results date for Accretion Pha.?

No Upcoming Board Meetings

Has Accretion Pha. declared dividend?

No Dividend History Available